Friday 1st February 2002 |
Text too small? |
Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.
"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.
CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.
No comments yet
MCY - Retirement of director
AIA - April 2025 Monthly traffic update
Sanford delivers an improved half year result
May 15th Morning Report
Devon Funds Morning Note - 14 May 2025
Winton Media Release - Ayrburn Film Hub
CEN - CONTACT ENERGY APPOINTS NEW CHIEF FINANCIAL OFFICER
VCT - Vector announces strategic review for its fibre business
May 14th Morning Report
Rua approves debt facility to accelerate sales.